Latest Articles

Publication Date
Trips taking kids harmed by Chernobyl to Nottingham forced to end - Yahoo News UK

Trips taking kids harmed by Chernobyl to Nottingham forced to end Yahoo News UK

Published: March 20, 2025, 6:58 p.m.
Endometrial Ablation Market Size to Hit USD 2.15 Bn by 2034 - Precedence Research

Endometrial Ablation Market Size to Hit USD 2.15 Bn by 2034 Precedence Research

Published: March 20, 2025, 1:41 p.m.
All layers of North West health service need to be adequately resourced - MacLochlainn - Ocean FM

All layers of North West health service need to be adequately resourced - MacLochlainn Ocean FM

Published: March 20, 2025, 9:40 a.m.
SCM-198 Inhibits EMS Development by Reversing Decreased Proportions of IFN-γ+T Cells and CCR5+T Cells.

Endometriosis is a common gynecological disease that causes severe pain and infertility. However, the available treatments for EMS are limited. SCM-198, a synthetic form of leonurine, possesses various abilities, including …

Published: March 20, 2025, midnight
Glypican3 and serglycin as potential biomarkers involved in the pathogenesis of ovarian endometriosis.

Endometriosis, a non-malignant gynecological disorder characterized by debilitating symptoms, displays several cancer-like characteristics, including metastatic behavior and extracellular matrix (ECM) remodeling. The dynamics of ECM are largely influenced by proteoglycans …

Published: March 20, 2025, midnight
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - The Malaysian Reserve

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy The Malaysian …

Published: March 19, 2025, 10:53 p.m.
Canada Approves KEYTRUDA For Advanced Endometrial Cancer - Evrim Ağacı

Canada Approves KEYTRUDA For Advanced Endometrial Cancer Evrim Ağacı

Published: March 19, 2025, 2:55 p.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Weekly Voice

Published: March 19, 2025, 11:20 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Canada …

Published: March 19, 2025, 11 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Finance

Published: March 19, 2025, 11 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!